Prostate Cancer- New Treatment - Published papers

Safety and Efficacy of Prostatic Artery Chemoembolization for Prostate Cancer- Initial Experience

 

 

 

 

Prostatic Artery Chemoembolization- A viable management option for Men-

Diagnosed with Prostate Cancer?

 

 

 

Journal of vascular and interventional radiology : JVIR. 2018 Jan 15

João Pisco, Tiago Bilhim, Nuno V Costa, Manuel Pinto Ribeiro, Lucia Fernandes, António G Oliveira

To evaluate outcome of prostatic artery chemoembolization for patients with prostate cancer (PCa).This single-center prospective cohort study was conducted between August 2013 and July 2016 in 20 patients with PCa who underwent chemoembolization. Mean patient age was 67.5 years ± 6.4. Gleason score was 6-10, and staging was T2N0M0. Fifteen patients refused prostatectomy and 5 wanted to stop hormonal therapy because of side effects. For chemoembolization, Chelidonium majus mother tincture 1 mL was slowly injected into the prostatic arteries. Docetaxel 1 mL and 150-300 μm Embosphere (Merit Medical Systems, Inc, South Jordan, Utah) microspheres 0.5 mL were thoroughly mixed, and the mixture was slowly injected by the same route. Embolization of prostatic arteries was finished with 150-300 μm Embosphere microspheres. Technical success was defined as bilateral prostatic artery embolization. Biochemical failure was defined as prostate specific antigen (PSA) decrease to < 2 ng/mL followed by recurrence when PSA increased to > 2 ng/mL within 1 month after success.Technical success was 80.0% (16/20 patients). Biochemical failure was 18.7% (3/16 patients). There was 1 short-term biochemical recurrence at 4 months and 2 midterm recurrences (12-18 months). Biochemical success at 12-18 months was 62.5% (10/16 patients). Adverse events (31.3%) included a small area (2 cm2) of bladder wall ischemia, which was removed by surgery (n = 1); transient acute urinary retention (n = 1) and urinary urgency (n = 1) for 1 week; sexual dysfunction (n = 2), which completely recovered after 10 and 12 months, respectively.

Prostatic artery chemoembolization allowed a biochemical response in patients with localized PCa and is a promising treatment.

Interventional Radiology Department, Hospital Saint Louis, Avenida David Mourão Ferreira 27, 4D, Lisbon, Lumiar 1750-220, Portugal., Interventional Radiology Department, Hospital Saint Louis, Avenida David Mourão Ferreira 27, 4D, Lisbon, Lumiar 1750-220, Portugal; Radiology Department, Nova Medical School, Lisbon, Portugal., Interventional Radiology Department, Hospital Saint Louis, Avenida David Mourão Ferreira 27, 4D, Lisbon, Lumiar 1750-220, Portugal; Radiology Department, Nova Medical School, Lisbon, Portugal. Electronic address: nunocosta@radiology.win ., Oncology Department, Hospital Da Cruz Vermelha Portuguesa, Lisbon, Portugal., Department of Pharmacy, Universidade Federal do Rio Grande do Norte, Natal, Brazil.

Partilhe este conteúdo

Leave your comment:

Prostate Cancer- New Treatment - Free Comunications

Abstract Nº: 271- Prostate arterial chemoembolization for prostate cancer- SIR 2017

 

 

NEW TREATMENT FOR PROSTATE CANCER – PROSTATIC ARTERY CHEMOEMBOLIZATION CIRSE 2017

 

João Pisco, Tiago Bilhim, Manuel Pinto Ribeiro, Amadeu Brigas, Lúcia Fernandes, Nuno Costa, António G. Oliveira

Purpose – To evaluate the short and mid term results of prostatic artery Chemoembolization (PACE) for patients with prostate cancer (Pca).

Materials and Methods – Between March 2015 and February 2017, 30 patients with Pca underwent PACE. Gleason score ranged between 6 and 10 and staging was T2NoMo.

For PACE, Chelidonium majus Mother-Tincture 1cc was injected and following that, Docetaxel 1cc mixed with Lipiodol 0.5 were injected in prostatic arteries. Embolization of these arteries was performed with Embospheres 150-300µm.

Results – Mean patients age was 68.4 y. Patients whose PSA did not decrease under 2 ng/mL after PACE were considered initial biochemical failure as occurred in 5 (16.7%) patients. Of the 25 patients with technical success there were 23 (92%) initial biochemical success and 2 (8%) initial biochemical failure. Between 1 and 12 months there were 5 (28%) additional patients with biochemical failure and 18 patients (72%) with biochemical success. Twelve patients were evaluated at mid-term between 12 and 18 months with 2 (16,6%) mid-term failures. From the 25 patients with technical success there were 16 (64%) with biochemical success. There was a major complication a bladder wall ischemia treated by surgery.

Conclusion – PACE for prostate cancer is a new, safe and promising outpatient procedure for Pca with good short and mid term results.

 

February 21, 2018- Dubai, Pan Arabe Interventional Radiology Association Congress Prostate Cancer.

Is there a role for catheter in prostate cancer?

Partilhe este conteúdo

Fatal error: Cannot redeclare mytheme_comment() (previously declared in /home/pg42638/public_html/martinspisco/activeapp/wp-content/themes/hslouis_v1/comments.php:4) in /home/pg42638/public_html/martinspisco/activeapp/wp-content/themes/hslouis_v1/comments.php on line 27